Mayo Clinic Proceedings Home


        In the article “Lipoprotein(a), Cardiovascular Disease, and Contemporary Management,” published in the November 2013 issue of Mayo Clinic Proceedings (2013;88(11):1294-1311), Lp(a) cholesterol and Lp(a)-C should read as Lp(a) throughout the article.

        Linked Article

        • Lipoprotein(a), Cardiovascular Disease, and Contemporary Management
          Mayo Clinic ProceedingsVol. 88Issue 11
          • Preview
            Elevated lipoprotein(a) (Lp[a]) is a causal genetic risk factor for cardiovascular disease. To determine if current evidence supports both screening and treatment for elevated Lp(a) in high-risk patients, an English-language search of PubMed and MEDLINE was conducted. In population studies, there is a continuous association between Lp(a) concentrations and cardiovascular risk, with synergistic effects when low-density lipoprotein (LDL) is also elevated. Candidates for Lp(a) screening include patients with a personal or family history of premature cardiovascular disease, familial hypercholesterolemia, recurrent cardiovascular events, or inadequate LDL cholesterol (LDL-C) responses to statins.
          • Full-Text
          • PDF